Rivaroxaban versus enoxaparin after total knee arthroplasty

The Lancet

Volumn 374, Issue 9691, 2009, Pages 682-

  Gómez Outes, Antonio ^a   Suárez Gea, M Luisa ^a   Blázquez Pérez, Antonio ^a   Pozo Hernández, Carmen ^a   Vargas Castrillón, Emilio ^a  

^a Parque Empresarial Las Mercedes   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ENOXAPARIN; RIVAROXABAN;

BLEEDING; CLINICAL PRACTICE; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TOTAL KNEE REPLACEMENT;

EID: 69249189869     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61552-X     Document Type: Letter

References (4)

1. Turpie A., Lassen M., Davidson B., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373 (2009) 1673-1680
2. Fisher W.D., Eriksson B.I., Bauer K.A., et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 97 (2007) 931-937
3. Wolowacz S.E., Roskell N.S., Plumb J.M., Caprini J.A., and Eriksson B.I. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 101 (2009) 77-85
4. FDA Cardiovascular & Renal Drugs Advisory Committee. Meeting ID: 2009-4418. http://www.fda.gov (accessed May 21, 2009).